Close

IMGN Financial Facts

Research and development: 32.91M
Research and development support: 1.35M
See Full Income Statement

Total shareholders' equity: -122.54M
Prepaid and other current assets: 7.48M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 4/25/24 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +73.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +51.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/2/23 Q323 $0.10$0.04 +$0.06$113.4M$103.68M N/A Details
2/12/21 Q420 $0.16-$0.10 +$0.26$85.8M$37.09M = Details
7/31/23 Q223 -$0.02-$0.13 +$0.11$77.4M$49.15M N/A Details
4/28/23 Q123 -$0.16-$0.25 +$0.09$49.9M$20.97M N/A Details
1/30/15 Q215 $0.16-$0.05 +$0.21$48.3M$37.3M N/A Details
2/14/20 Q419 $0.03-$0.05 +$0.08$44.9M$29.33M = Details
3/1/23 Q422 -$0.23-$0.30 +$0.07$41.17M$17.43M N/A Details
2/9/18 Q417 -$0.11-$0.12 +$0.01$39.45M$32.71M = Details